Appl. No. 09/868,930 Reply to Office Action of March 31, 2003 Atomey Dockt: P66806US0

REMARKS

In this supplemental response, Applicant respectfully submits the Article for Examiner to consider the level of ordinary skill in the art regarding the relationship of the thromboxan A2 with cardio-vascular, blood, pulmonary, reproduction and renal diseases, and the knowledge that an inhibitor to a thromboxan A2 provides treatment for these diseases.

As indicated in the Article and the references listed therein, "an overproduction of thromboxan A2 revealed by an increase of its urinary and blood metabolites has been demonstrated in patients with various disease states such as: severe peripheral vascular disease, myocardial infarction, unstable angina, pregnancy-induced hypertension and preeclampsia, asthma, lupus nephritis, thrombosis and coronary thrombotic syndrome." (Table 2) "Therefore, drugs reducing the biological effects of thromboxane A2 are expected to provide a therapeutical benefit in diseases associated with an increased thromboxane A2 production..." (page 611) The Article then reviews the evolution in discovering thromboxane A2's pathological effects and development of thromboxane A2 inhibitors. In particular, the Article provides various clinical trials and drugs on markets that acts as thromoboxane A2 inhibitors to treat various diseases (page 616, col. 1, lines 1-11; page 617, col. 2, lines 16-21; page 621, col. 1, line 14 (bottom) through col. 2, line 14 and lines 26-34; page 623, col. 2, lines 14-26).

Therefore, as the Article and the references listed therein shows, it is well known in the art that a thromboxan A2 relates to cardio-vascular and blood, pulmonary, reproduction and renal diseases and an inhibitor to a thromboxan A2 provide treatment for these diseases. Due to the level of the skill in the art, there is no undue experimentation to practice the invention as claimed.

Attorney Dockt: P66806US0

Appl. No. 09/868,930 Reply to Office Action of March 31, 2003

All claims are now present for examination and favorable reconsideration is respectfully requested in view of all the preceding amendments. The application is now in condition for allowance, and prompt action toward that end is respectfully solicited.

Respectfully submitted,

JACOBSON HOLMAN PLLC

Date: October 3, 2003 (202) 638-6666 400 Seventh Street, N.W. Washington, D.C. 20004 JCH/jc

Atty. Dkt. No.: P66806US0

John C. Holman

Registration No. 22,769

RECEIVED CENTRAL FAX CENTER

OCT 0 6 2003

OFFICIAL